The statistical results of western blot and IHC demonstrated that the P-EGFR expression of the cetuximab-treated group was significantly lower than that of the PBS-treated group (Fig. 5i–j, Supplementary Figs. 63–64), matching well with the EGFR activity evaluated by the ETTE probe in tumor tissues (Fig. 5k). The gene discussed is EGFR; the disease is neoplasm.